Salami Taofik Atanda TİTİLOPE, Samuel Sunday OLOWO, Olarewaju David OLANIYI, Omeife HENRY, Ozeigbe Odigie ENAHORO, Momoh MOJEED

Safety in the working environment– The place of post exposure prophylaxis against HIV infection

HIV virüsü taşıyanlarla beraber çalışanşlarda mesleki olarak HIV virüsünden etkilenme olasılığı bulunmaltadır. Bu durum özellikle sağlık çalışanlarında daha fazla görülmektedir. HIV etkilenimi sonrası profilaksi (PEP); HIV vulaşmış malzemelere kaza ile mesleki ve mesleki olmayan temas sırasında ortaya çıkan HIV enfeksiyonunun sıklığını azaltacak ikincil HIV önleme formudur. Birçok çalışmada etkilenim sonrası kemoterapinin koruyucu etkinliğini destekleyen kanıtlar bulunmuştur. Ancak HIV yayılmasını önlemede %100 etkili değildir. HIV etkileniminden kaynaklanacak mesleki riskleri en aza indirmek için alınan temel evrensel önlemler sonrasında, HIV virüsüne maruziyetin gerçekleşmesi durumunda kullanımı uygundur.

Çalışma ortamı güvenliği–HIV enfeksiyonundan korunmada maruziyet sonrası profilaksinin yeri

Occupational exposure to HIV virus is a possibility to all workers working with patients having the virus. This is particularly more apparent when working within the healthcare setting. HIV post exposure prophylaxis (PEP) is a form of secondary HIV prevention that may reduce the incidence of HIV infection occurring during occupational and non–occupational accidental contact with infectious materials. A lot of studies have shown encouraging evidence of post exposure chemo prophylactic efficacy. It is however not 100% effective in preventing HIV transmission. Apart from the basic universal precautions to minimize occupational exposures to HIV virus, the use of post exposure prophylaxis is important when such exposures do occur.

PDF

___

1. Bateman C. Health carers cracking under HIV/AIDS workload. S Afr Med J. 2003; 93(10): 734–6.
2. Elliot R, Jurgens R. Rapid HIV screening at the point of care: legal and ethical questions. Montreal. Canadian HIV/AIDS Legal Network, 2000.
3. Laboratory Centre for Disease Control. Proceedings of the consensus conference on infected health care workers: risk for transmission of bloodborne pathogens. Can Commun Dis Rep. 1998; 24(Suppl 4).
4. Kiertiburanakul S, Wannaying B, Tonsuttakul S, Kehachindawat P, Apivanich S, Somsakul S, at al. Use of HIV Postexposure Prophylaxis in healthcare workers after occupational exposure: a Thai university hospital setting. J Med Assoc Thai. 2006; 89(7): 974–8.
5. Kowalska JD, Firlag–Burkacka E, Niezabitowska M, Bakowska E, Ignatowska A, Pulik P, at al. Post–exposure prophylaxis of HIV infection in out–patient clinic of hospital for infectious diseases in Warsaw in 2001–2002. Przegl Epidemiol. 2006; 60(4): 789–94.
6. Ann ND, Ciesielski CA, Metler RP, Hammet TA, Li J, Fleming PA. Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States. Infect Control Hosp Epidemiol. 2003; 24: 86–96.
7. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med. 1997; 102(suppl 5B): 9–15.
8. Ippolito G, Puro V, De Carli G, Italian Study Group on Occupational Risk of HIV Infection. The risk of occupational human immunodeficiency virus in health care workers. Arch Int Med. 1993; 153: 1451–8.
9. CDC. Update: human immunodeficiency virus infections in health–care workers exposed to blood of infected patients. MMWR. 1987; 36: 285–9
10. Fahey BJ, Koziol DE, Banks SM, Henderson DK. Frequency of nonparenteral occupational exposures to blood and body fluids before and after universal precautions training. Am J Med. 1991; 90: 145–53
11. Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV–1) associated with clinical exposures: a prospective evaluation. Ann Intern Med. 1990; 113: 740–6.
12. Cardo DM, Culver DH, Ciesielski CA, et al. A case–control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997; 337: 1485–90.
13. Mast ST, Woolwine JD, Gerberding JL. Efficacy of gloves in reducing blood volumes transferred during simulated needlestick injury. J Infect Dis. 1993; 168: 1589–92.
14. Pinto LA, Landay AL, Berzofsky JA, Kessler HA, Shearer GM. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIVcontaminated blood. Am J Med. 1997; 102(suppl 5B): 21–4.
15. Clerici M, Giorgi JV, Chou C–C, et al. Cell– mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV–1. J Infect Dis. 1992; 165: 1012–9.
16. Ranki A, Mattinen S, Yarchoan R, et al. T–cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV– exposed sexual partners. AIDS. 1989; 3: 63–9.
17. Cheynier R, Langlade–Demoyen P, Marescot M– R, et al. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus–1–infected mothers. Eur J Immunol. 1992; 22: 2211–7.
18. Kelker HC, Seidlin M, Vogler M, Valentine FT. Lymphocytes from some long–term seronegative heterosexual partners of HIV–infected individuals proliferate in response to HIV antigens. AIDS Res Hum Retroviruses. 1992; 8: 1355–9.
19. Langlade–Demoyen P, Ngo–Giang–Huong N, Ferchal F, Oksenhendler E. Human immunodeficiency virus (HIV) nef–specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV–infected patients. J Clin Invest. 1994; 93: 1293–7.
20. Rowland–Jones S, Sutton J, Ariyoshi K, et al. HIV–specific cytotoxic T–cells in HIV–exposed but uninfected Gambian women. Nat Med. 1995; 1: 59–64.
21. D’Amico R, Pinto LA, Meyer P, et al. Effect of zidovudine postexposure prophylaxis on the development of HIV–specific cytotoxic T– lymphocyte responses in HIV–exposed healthcare workers. Infect Control Hosp Epidemiol. 1999; 20: 428–30.
22. Abel S, Ce´saire R, Cales–Quist D, Be´ra O, Sobesky G, Cabie´ A. Occupational Transmission of Human Immunodeficiency Virus and Hepatitis C Virus after a Punch. Clinical Infectious Diseases. 2000; 31: 1494–5.
23. Tyndall MW, Schechter MT. HIV testing of patients: let's waive the waiver. CMAJ. 2000; 162(2): 210–1.
24. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996; 183: 215–25.
25. McClure HM, Anderson DC, Ansari AA, Fultz PN, Klumpp SA, Schinazi RF. Nonhuman primate models for evaluation of AIDS therapy. In: AIDS: anti–HIV agents, therapies and vaccines. Ann N Y Acad Sci. 1990; 616: 287–98.
26. Böttiger D, Johansson N–G, Samuelsson B, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV–2 infection in cynomolgus monkeys by pre–and postexposure administration of BEA–005. AIDS. 1997; 11: 157–62.
27. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig–tailed macaques to a human– derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000; 74: 9771–5.
28. Sinet M, Desforges B, Launay O, Colin JN, Pocidalo JJ. Factors influencing zidovudine efficacy when administered at early stages of Friend virus infection in mice. Antiviral Res. 1991; 16: 163–71.
29. Ruprecht RM, Bronson R. Chemoprevention of retroviral infection: success is determined by virus inoculum strength and cellular immunity. DNA Cell Biol. 1994; 13: 59–66.
30. Fazely F, Haseltine WA, Rodger RF, Ruprecht RM. Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon: failure after inoculating rhesus monkeys with a high dose of SIV. J Acquir Immune Defic Syndr. 1991; 4: 1093–7.
31. Böttiger D, Oberg B. Influence of the infectious dose of SIV on the acute infection in cynomolgus monkeys and on the effect of treatment with 3'– fluorothymidine. Seattle. Symposium on Nonhuman Primate Models for AIDS, 1991.
32. Martin LN, Murphey–Corb M, Soike KF, Davison– Fairburn B, Baskin GB. Effects of initiation of 3'– azido,3'–deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis. 1993; 168: 825–35.
33. Shih CC, Kaneshima H, Rabin L, et al. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID–hu mice in a timedependent manner. J Infect Dis. 1991; 163: 625–7.
34. Mathes LE, Polas PJ, Hayes KA, Swenson CL, Johnson S, Kociba GJ. Pre–and postexposure chemoprophylaxis: evidence that 3'–azido– 3'dideoxythymidine inhibits feline leukemia virus disease by a drug–induced vaccine response. Antimicrob Agents Chemother. 1992; 36: 2715– 21.
35. Tavares L, Roneker C, Johnston K, Lehrman SN, de Noronha F. 3'–azido–3'–deoxythymidine in feline leukemia virus–infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res. 1987; 47: 3190–4.
36. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)–9–(2– phosphonylmethoxypropyl) adenine. Science 1995; 270: 1197–9.
37. Tsai CC, Emau P, Follis KE. Effectiveness of postinoculation_(R)_9_2_phosphonylmethoxypro pyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998; 72: 4265–73.
38. Le Grand R, Vaslin B, Larghero J. Post–exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS. 2000; 14: 1864–6.
39. LaFon SW, Mooney BD, McMullen JP. A double– blind, placebo–controlled study of the safety and efficacy of retrovir® (zidovudine, ZDV) as a chemoprophylactic agent in health care workers exposed to HIV. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta. American Society for Microbiology, 1990, p. 167.
40. Connor EM, Sperling RS, Gelber R. Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331: 1173–80.
41. Sperling RS, Shapiro DE, Coombs RW. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996; 335: 1621–9.
42. Shaffer N, Chuachoowong R, Mock PA, et al. Short–course zidovudine for perinatal HIV– 1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 1999; 353: 773–80.
43. Saba J, PETRA Trial Study Team. Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent mother–to–child transmission of HIV–1: the PETRA trial. 6th Conference on Retroviruses and Opportunistic Infections. Chicago. Foundation for Retrovirology and Human Health in scientific collaboration with the National Institute of Allergy and Infectious Diseases and CDC, 1999.
44. Wade NA, Birkhead GS, Warren BL. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998; 339: 1409–14.
45. Musoke P, Guay LA, Bagenda D. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV–1–infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999; 13: 479–86.
46. Guay LA, Musoke P, Fleming T. Intrapartum and neonatal single–dose nevirapine compared with zidovudine for prevention of mother–to–child transmission of HIV–1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999; 354: 795–802.
47. Benais JP, Miara A, Brion S. Treatment of sexual assault A multicentrique study in emergency medico–legal units in the Paris region. Durban. XIII International AIDS Conference, 2000, p. TuOrC314.
48. Debab Y, Fartoukh C, Abboud P, Gueit I, Borsa– Lebas F. HIV post–exposure prophylaxis: influence of the mode of exposure on the compliance and tolerance of the procedure. Program and abstracts of the XIII International AIDS Conference; July 9–14, 2000; Durban, South Africa. Session ThPpC1448.
49. Meel BL. HIV/AIDS post–exposure prophylaxis (PEP) for victims of sexual assault in South Africa. Med Sci Law. 2005; 45(3): 219–24
50. Oladokun R, Brown BJ, Osinusi K, Akingbola TS, Ajayi SO, Omigbodun OO. A case of human bite by an 11–year old HIV positive girl in a paediatrics ward. Afr J Med Med Sci. 2008; 37(1): 81–5
51. Panlilio AL, Cardo DM, Campbell S, Srivastava P, NaSH Surveillance Group. Experience of health care workers taking antiretroviral agents as postexposure prophylaxis for occupational exposure to HIV. Atlanta. Proceedings of the 1999 National HIV Prevention Conference, 1999.
52. Wang SA, Panlilio AL, Doi PA, et al. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV postexposure prophylaxis registry. Infect Control Hosp Epidemiol. 2000; 21: 780
53. Jochimsen EM, Srivastava PU, Campbell SR, Cardo DM, NaSH Surveillance Group. Postexposure prophylaxis (PEP) use among health care workers (HCWs) after occupational exposures to blood. Montreal. 4th ICOH International Conference on Occupational Health for Health Care Workers, 1999.
54. Critchley SE, Srivastava PU, Campbell SR, Cardo DM, NaSH Surveillance Group Postexposure prophylaxis use among healthcare workers who were exposed to HIVnegative source persons. 4th Decennial International Conference on Nosocomial and Healthcare– Associated Infections. Atlanta. CDC in conjunction with the 10th Annual Meeting of SHEA, 2000, p. 126.
55. Steger KA, Swotinsky R, Snyder S, Craven DE. Recent experience with post–exposure prophylaxis (PEP) with combination antiretrovirals for occupational exposure (OE) to HIV. 35th annual meeting of the Infectious Diseases Society of America. Alexandria. Infectious Diseases Society of America, 1997, p. 161.
56. Henry K, Acosta EP, Jochimsen E. Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis [Letter]. Ann Intern Med. 1996; 124: 855.
57. Johnson S, Baraboutis JG; Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers [Letters]. JAMA. 2000; 284: 2722–3.
58. Gerberding JL, Henderson DK. Management of occupational exposures to bloodborne pathogens: hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Clin Inf Dis. 1992; 14: 1179–85.
59. Armstrong K, Gorden R, Santorella G. Occupational exposures of health care workers (HCWs) to human immunodeficiency virus (HIV): stress reactions and counseling interventions. Soc Work Health Care. 1995; 21: 61–80.
60. Henry K, Campbell S, Jackson B, et al. Long– term follow–up of health care workers with work– site exposure to human immunodeficiency virus [Letter]. JAMA. 1990; 263: 1765.
61. AIDS/TB Committee of the Society for Healthcare Epidemiology of America. Management of healthcare workers infected with hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or other bloodborne pathogens. Infect Control Hosp Epidemiol. 1997; 18: 349–63.
62. Jochimsen EM. Failures of zidovudine postexposure prophylaxis. Am J Med. 1997; 102(suppl 5B): 52–5.
63. Pratt RD, Shapiro JF, McKinney N, Kwok S, Spector SA. Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury. J Infect Dis. 1995; 172: 851–4.
64. Lot F, Abiteboul D. Infections professionnelles par le V.I.H. en France chez le personnel de santé-le point au 30 juin 1995. Bulletin Épidémiologique Hebdomadiaire. 1995; 44: 193–4.
65. Weisburd G, Biglione J, Arbulu MM, Terrazzino JC, Pesiri A. HIV seroconversion after a work place accident and treated with zidovudine. Vancouver. XI International Conference on AIDS. 1996, p. 460.
66. Perdue B, Wolderufael D, Mellors J, Quinn T, Margolick J. HIV–1 transmission by a needlestick injury despite rapid initiation of four–drug postexposure prophylaxis. 6th Conference on Retroviruses and Opportunistic Infections. Chicago. Foundation for Retrovirology and Human Health in scientific collaboration with the National Institute of Allergy and Infectious Diseases and CDC, 1999, p. 107.
67. Lot F, Abiteboul D. Occupational HIV infection in France Montreal. 4th ICOH International Conference on Occupational Health for Health Care Workers, 1999.
68. Beltrami EM, Luo C–C, Dela Torre N, Cardo DM. HIV transmission after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. 4th Decennial International Conference on Nosocomial and Healthcare–Associated Infections in conjunction with the 10th Annual Meeting of SHEA. Atlanta. CDC, 2000, p. 125–126.